Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apixaban vs Enoxaparin in Microsurgical Breast Reconstruction
NCT04504318Phase 2Completed
- Sponsor
- Stanford University
- Start
- Aug 2020
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of apixaban in venous thromboembolism (VTE) (2 arms), sponsored by Stanford University. Primary endpoint: Number of Participants With Bleeding Events at 90 days. Started Aug 2020; status: completed.
02
Drugs
apixaban
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT04504318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04504318.